Promega, JA3072, ICOS Bioassay

Measure Potency and Stability of Biologics Designed to Activate ICOS
Use with Bio-Glo-NL™ Luciferase Assay System
Prequalified according to ICH guidelines
96- and 384-well plate compatible
Available in convenient thaw-and-use format
Specifications：
ICOS Effector Cells J328A 1 × 1 vial
Fetal Bovine Serum J121A 1 × 4ml
RPMI 1640 Medium G708A 1 × 36ml
Bio-Glo-NL™ Luciferase Assay Buffer J308A 1 × 10ml
Bio-Glo-NL™ Luciferase Assay Substrate J309A 1 × 200μl
ICOS Effector Cells J328A 5 × 1 vial
Fetal Bovine Serum J121A 5 × 4ml
RPMI 1640 Medium G708A 5 × 36ml
Bio-Glo-NL™ Luciferase Assay Buffer J308A 5 × 10ml
Bio-Glo-NL™ Luciferase Assay Substrate J309A 5 × 200μl
FcγRIIb aAPC/CHO-K1 (CPM) J325A 2 × 1ml
ICOS Effector Cells (CPM) J327A 2 × 1ml
Control Ab, Anti-ICOS K124A 1 × 50μg
The ICOS Bioassay is a bioluminescent cell-based assay used to measure the potency and stability of ligands or agonist antibodies that activate ICOS. ICOS (CD278) binds to its ligand ICOSL (B7-H2, CD275), which is constitutively expressed on B cells, monocytes and dendritic cells, and can be induced on endothelial and epithelial cells during inflammation. ICOS co-stimulation induces the production of effector T cell cytokines such as interferon (IFN)-γ, interleukin (IL)-4 and IL-10.
The ICOS Bioassay reflects the mechanism of action (MOA) of biologics designed to activate ICOS.